- Home
- LUCD vs KRRO Comparison
LUCD vs KRRO Comparison
Compare LUCD & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCD | KRRO |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.8M | 187.9M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LUCD | KRRO |
|---|---|---|
| Price | $0.97 | $11.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $4.13 | ★ $34.80 |
| AVG Volume (30 Days) | ★ 1.7M | 293.6K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,346,000.00 | ★ $6,392,000.00 |
| Revenue This Year | $115.58 | N/A |
| Revenue Next Year | $130.54 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 79.00 | ★ 181.46 |
| 52 Week Low | $0.90 | $5.20 |
| 52 Week High | $1.63 | $55.89 |
Technical Indicators
Market Signals| Indicator | LUCD | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 44.36 | 41.90 |
| Support Level | N/A | $10.32 |
| Resistance Level | $1.11 | $14.78 |
| Average True Range (ATR) | 0.07 | 1.12 |
| MACD | -0.01 | -0.32 |
| Stochastic Oscillator | 16.07 | 12.44 |
Price Performance
Historical ComparisonAbout LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.